Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 12/20 | 0.51 |
| ▸ | NPY1R | P25929 | 7/20 | 0.51 |
| ▸ | NPY2R | P49146 | 5/20 | 0.51 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.51 |
| ▸ | FURIN | P09958 | 5/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.42 |
| ▸ | CTSD | P07339 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30339863 | 1.00 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RFURIN | |
| SCHEMBL29732335 | 1.00 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RFURIN | |
| SCHEMBL30305367 | 1.00 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RFURIN | |
| SCHEMBL30148454 | 1.00 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RFURIN | |
| SCHEMBL30945400 | 1.00 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RFURIN | |
| SCHEMBL29799775 | 1.00 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RFURIN | |
| SCHEMBL1527412 | 1.00 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RFURIN | |
| SCHEMBL30945410 | 1.00 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RFURIN | |
| SCHEMBL1527410 | 1.00 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RFURIN | |
| SCHEMBL30305284 | 1.00 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RFURIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250277002-A1 | ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES AND METHODS OF USE | PEPTILOGICS, INC. | 2025-09-04 | — | — | US | claimed |
| US-20230107222-A1 | ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES AND METHODS OF USE | PEPTILOGICS, INC. | 2023-04-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250277002-A1 | ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES AND METHODS OF USE | NGLY1, PRF1, LNPEP | NPY4R 3510/4885NPY1R 3504/4885NPY2R 3813/4885 |
| US-20230107222-A1 | ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES AND METHODS OF USE | NGLY1, PRF1, LNPEP | NPY4R 3510/4885NPY1R 3504/4885NPY2R 3813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.